Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Lilly to buy Loxo Oncology in $8 billion cancer push

Published 07/01/2019, 14:55
© Reuters. FILE PHOTO: The logo and ticker for Eli Lilly and Co. are displayed on a screen on the floor of the NYSE in New York
JPM
-
LLY
-
BAYGN
-
CELG
-
BMY
-
LOXO
-

By Tamara Mathias

(Reuters) - Eli Lilly and Co (N:LLY) said on Monday it would buy Loxo Oncology Inc (O:LOXO) for about $8 billion (£6.2 billion) in cash, making its biggest bet on a cancer therapy market expected to be worth several billions of dollars.

The deal follows Bristol-Myers Squibb Co (N:BMY) agreement last week to buy Celgene Corp (O:CELG) for $74 billion, and gives Lilly access to Loxo's portfolio of targeted medicines that treat cancers caused by rare gene mutations.

The portfolio is centred around the company's first commercial medicine, Vitrakvi, which is sold in partnership with Bayer AG (DE:BAYGn).

Shares of Lilly were down 2.5 percent while those of Loxo were trading close the offer price of $235 per share, which was at a 68 percent premium to the stock's Friday close.

"The acquisition of Loxo, along with last weeks acquisition of Celgene, may represent the cream of the crop in biotech being harvested by big pharma," IFS Securities analyst David Bouchey said.

"The size of the deal may indicate Lily's willingness to pay up to out-bid the competition."

But BMO Capital Markets analyst Alex Arfaei said the $8 billion valuation seemed high as Loxo was not profitable yet and Wall Street expects revenue of $1 billion only by 2023.

The company bought Armo Biosciences Inc, a developer of drugs that help the body's immune system to fight cancer, for $1.6 billion last year and indicated that it was on the lookout for similar acquisitions.

Indianapolis, Indiana-based Lilly's oncology portfolio includes lung cancer drug Alimta, Erbitux, a treatment for certain types of colorectal cancers and gastric cancer medicine Cyramza. Alimta brought in $520.5 million in the latest reported quarter.

Loxo's Vitrakvi, priced at $32,800 per month, could eventually generate over $750 million in sales along with another similar drug, LOXO-195, according to brokerage Piper Jaffray & Co.

Loxo is also developing a drug that targets a rare gene fusion mutation known as RET, seen in thyroid, lung and other cancers.

Lilly's offer of $235 per share in cash represents a premium of about 68 percent to Loxo's Friday close. Loxo's shares jumped to $230 before the bell, while those of Lilly dropped 2.7 percent to $111.60.

Loxo's shares have run up nearly 65 percent over the past 12 months, while Lilly's stock has surged 34 percent in the same time.

© Reuters. FILE PHOTO: The logo and ticker for Eli Lilly and Co. are displayed on a screen on the floor of the NYSE in New York

The deal was announced just ahead of the start of the annual JPMorgan (NYSE:JPM) healthcare conference in San Francisco, scheduled to begin on Monday morning.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.